Study details
Enrolling now
AU409 for Advanced Liver Cancers or Solid Tumors
University of Southern California
NCT IDNCT05791448ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
36
Study length
about 4 years
Ages
18+
Locations
2 sites in CA
About this study
This trial is testing the safety, side effects, and best dose of a new intervention called AU409 in people with advanced liver cancers or solid tumors that have spread to the liver. The goal is to see if AU409 can stop cancer from growing and spreading.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take RNA Transcription Modulator AU-409
- 2.Undergo Biospecimen Collection
- 3.Undergo Computed Tomography
- +1 more
PhasePhase 1
Primary goalIncidence of adverse events
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Incidence of adverse events, Maximum Tolerated Dose
Secondary: Pharmacokinetics evaluation - Peak plasma concentration (Cmax), Pharmacokinetics evaluation - Peak time (Tmax)
Procedures
diagnostic, imaging
Body systems
Oncology